Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $95

Benzinga · 3d ago
Wells Fargo analyst Yanan Zhu maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $100 to $95.